Current Perspectives on HIV-1 Antiretroviral Drug Resistance

被引：126

作者：

Iyidogan, Pinar ^{[1
]}

Anderson, Karen S. ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA

来源：

VIRUSES-BASEL | 2014年 / 6卷 / 10期

基金：

美国国家卫生研究院;

关键词：

HIV-1; antiviral therapy; drug resistance; evolution; lethal mutagenesis; resistance monitoring; IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE REVERSE-TRANSCRIPTASE; AMINO-ACID SUBSTITUTIONS; EXPERIENCED HIV-1-INFECTED PATIENTS; DEPENDENT PRIMER UNBLOCKING; SMALL-MOLECULE INHIBITOR; CLEAVAGE SITE MUTATIONS; RNA-POLYMERASE-II; DYNAMICS IN-VIVO; LETHAL MUTAGENESIS;

D O I：

10.3390/v6104095

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.

引用

页码：4095 / 4139

页数：45

共 308 条

[1] Molecular Basis for Drug Resistance in HIV-1 Protease [J].

Ali, Akbar ;

Bandaranayake, Rajintha M. ;

Cai, Yufeng ;

King, Nancy M. ;

Kolli, Madhavi ;

Mittal, Seema ;

Murzycki, Jennifer F. ;

Nalam, Madhavi N. L. ;

Nalivaika, Ellen A. ;

Oezen, Ayseguel ;

Prabu-Jeyabalan, Moses M. ;

Thayer, Kelly ;

Schiffer, Celia A. .

VIRUSES-BASEL, 2010, 2 (11) :2509-2535

[2] Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1 [J].

Althaus, CL ;

Bonhoeffer, S .

JOURNAL OF VIROLOGY, 2005, 79 (21) :13572-13578

[3] Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 [J].

Anastassopoulou, Cleo G. ;

Ketas, Thomas J. ;

Klasse, Per Johan ;

Moore, John P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (13) :5318-5323

[4] Viral error catastrophe by mutagenic nucleosides [J].

Anderson, JP ;

Daifuku, R ;

Loeb, LA .

ANNUAL REVIEW OF MICROBIOLOGY, 2004, 58 :183-205

[5] TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 [J].

Andries, K ;

Azijn, H ;

Thielemans, T ;

Ludovici, D ;

Kukla, M ;

Heeres, J ;

Janssen, P ;

De Corte, B ;

Vingerhoets, J ;

Pauwels, R ;

de Béthune, MP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4680-4686

[6]

[Anonymous], 2014, Guidance on the development of early writing in reception classes, P1

[7]

[Anonymous], **NON-TRADITIONAL**

[8] Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT):: Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase [J].

Arion, D ;

Kaushik, N ;

McCormick, S ;

Borkow, G ;

Parniak, MA .

BIOCHEMISTRY, 1998, 37 (45) :15908-15917

[9] Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline [J].

Asahchop, Eugene L. ;

Wainberg, Mark A. ;

Oliveira, Maureen ;

Xu, Hongtao ;

Brenner, Bluma G. ;

Moisi, Daniela ;

Ibanescu, Ilinca R. ;

Tremblay, Cecile .

AIDS, 2013, 27 (06) :879-887

[10] Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors [J].

Asahchop, Eugene L. ;

Wainberg, Mark A. ;

Sloan, Richard D. ;

Tremblay, Cecile L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (10) :5000-5008

← 1 2 3 4 5 6 7 8 9 10 →